An analysis of major depressive disorder, covering diagnostic criteria, prevalence statistics across demographics, and ...
Navacaprant did not statistically significantly improve MADRS total score or SHAPS total score compared with placebo. Topline data were announced from a phase 3 trial evaluating navacaprant for the ...
Stocktwits on MSN
Biohaven’s phase II depression trial falls short, but analysts downplay impact – Wall Street looks ahead to epilepsy data
Analyst Myles Minter noted that the company’s pivotal Phase III study of BHV-7000 in focal-onset epilepsy in the first half ...
Major depressive disorder (MDD) is a debilitating psychiatric condition characterized by a persistently low mood, a lack of ...
Major depressive disorder (MDD) is a leading cause of disability in millions of people worldwide. Importantly, the gut microbiome can contribute to stress-related responses in patients experiencing ...
Spectral speech features may serve as noninvasive biomarkers for monitoring attention and executive function in major depressive disorder.
Spravato (esketamine) is a nasal spray used for depression and was approved by the FDA in 2019. It is specifically for treatment-resistant depression, meaning depression symptoms that have not gotten ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback